The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Date of Patent:
Oct. 13, 2020

Filed:

Mar. 04, 2019
Applicant:

Ohio State Innovation Foundation, Columbus, OH (US);

Inventor:

Pravin T. P. Kaumaya, Westerville, OH (US);

Assignee:
Attorney:
Primary Examiner:
Int. Cl.
CPC ...
C07K 1/00 (2006.01); C07K 14/72 (2006.01); A61K 9/00 (2006.01); A61K 39/00 (2006.01); C07K 16/28 (2006.01); C12Q 1/6883 (2018.01); C07K 16/32 (2006.01); A61K 47/65 (2017.01); A61K 47/64 (2017.01); A61K 47/34 (2017.01); A61K 47/44 (2017.01); C07K 14/435 (2006.01); C07K 14/475 (2006.01); C07K 14/82 (2006.01); A61K 38/00 (2006.01);
U.S. Cl.
CPC ...
C07K 14/72 (2013.01); A61K 9/0019 (2013.01); A61K 39/0005 (2013.01); A61K 39/0011 (2013.01); A61K 47/34 (2013.01); A61K 47/44 (2013.01); A61K 47/646 (2017.08); A61K 47/65 (2017.08); C07K 14/435 (2013.01); C07K 14/475 (2013.01); C07K 14/721 (2013.01); C07K 14/82 (2013.01); C07K 16/2863 (2013.01); C07K 16/32 (2013.01); C12Q 1/6883 (2013.01); A61K 38/00 (2013.01); A61K 2039/505 (2013.01); A61K 2039/545 (2013.01); A61K 2039/5555 (2013.01); A61K 2039/55566 (2013.01); A61K 2039/585 (2013.01); A61K 2039/6075 (2013.01); A61K 2039/627 (2013.01); A61K 2039/70 (2013.01); C07K 2317/732 (2013.01);
Abstract

Provided herein are HER-3, HER-1 and IGF-1R B cell epitopes, peptide mimics, chimeric peptides and multivalent peptides. In some embodiments, the chimeric peptides include one or more HER-3, HER-1 and/or IGF-1R B cell epitopes, a linker, and a T helper cell (Th cell) epitope. Pharmaceutical compositions are also provided that contain one or more HER-3, HER-1 and/or IGF-1R chimeric peptides, and optionally, one or more HER-2 chimeric peptides and/or VEGF peptides. Also included herein are methods of treating a cancer using the HER-3, HER-1 and IGF-1R B cell epitopes, chimeric peptides and multivalent peptides.


Find Patent Forward Citations

Loading…